James E Brown
Company: DURECT Corporation
Job title: DVM
Seminars:
Results of a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability & Pharmacodynamics of the Fructokinase Inhibitor PF-06835919 Administered Daily for 16 Weeks in Adults with NAFLD & T2DM 2:00 pm
• Revealing results of nonclinical studies and a prior 6-week clinical study in patients with NALFD suggest that the orally administered fructokinase inhibitor PF-06835919 may have the potential to lower liver fat content and improve markers of insulin sensitivity. • Understanding the steps taken to further assess the potential utility of PF-06835919 for the treatment…Read more
day: Day 1 Stream 3 PM